These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 23771499)

  • 1. Gemigliptin, a novel dipeptidyl peptidase 4 inhibitor: first new anti-diabetic drug in the history of Korean pharmaceutical industry.
    Kim SH; Lee SH; Yim HJ
    Arch Pharm Res; 2013 Oct; 36(10):1185-8. PubMed ID: 23771499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A fixed-dose combination tablet of gemigliptin and metformin sustained release has comparable pharmacodynamic, pharmacokinetic, and tolerability profiles to separate tablets in healthy subjects.
    Park SI; Lee H; Oh J; Lim KS; Jang IJ; Kim JA; Jung JH; Yu KS
    Drug Des Devel Ther; 2015; 9():729-36. PubMed ID: 25678778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of gemigliptin, a dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes mellitus inadequately controlled with combination treatment of metformin and sulphonylurea: a 24-week, multicentre, randomized, double-blind, placebo-controlled study (TROICA study).
    Ahn CH; Han KA; Yu JM; Nam JY; Ahn KJ; Oh TK; Lee HW; Lee DH; Kim J; Chung CH; Park TS; Kim BJ; Park SW; Park HK; Lee KJ; Kim SW; Park JH; Ko KP; Kim CH; Lee H; Jang HC; Park KS
    Diabetes Obes Metab; 2017 May; 19(5):635-643. PubMed ID: 28026912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic and pharmacodynamic interaction between gemigliptin and metformin in healthy subjects.
    Shin D; Cho YM; Lee S; Lim KS; Kim JA; Ahn JY; Cho JY; Lee H; Jang IJ; Yu KS
    Clin Drug Investig; 2014 Jun; 34(6):383-93. PubMed ID: 24627290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic Interactions Between Gemigliptin and Metformin, and Potential Differences in the Pharmacokinetic Profile of Gemigliptin Between the Mexican and Korean Populations: A Randomized, Open-label Study in Healthy Mexican Volunteers.
    Conde-Carmona I; García-Medina S; Jiménez-Vargas JM; Martínez-Muñoz A; Lee SH
    Clin Ther; 2018 Oct; 40(10):1729-1740. PubMed ID: 30249366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of initial combination therapy with gemigliptin and metformin compared with monotherapy with either drug in patients with type 2 diabetes: A double-blind randomized controlled trial (INICOM study).
    Lim S; Han KA; Yu J; Chamnan P; Kim ES; Yoon KH; Kwon S; Moon MK; Lee KW; Kim DJ; Kim M; Wongtanate M; Kim EY; Kim SH; Lee MK;
    Diabetes Obes Metab; 2017 Jan; 19(1):87-97. PubMed ID: 27619558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological profiles of gemigliptin (LC15-0444), a novel dipeptidyl peptidase-4 inhibitor, in vitro and in vivo.
    Kim SH; Jung E; Yoon MK; Kwon OH; Hwang DM; Kim DW; Kim J; Lee SM; Yim HJ
    Eur J Pharmacol; 2016 Oct; 788():54-64. PubMed ID: 27298192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of gemigliptin as add-on therapy to insulin, with or without metformin, in patients with type 2 diabetes mellitus (ZEUS II study).
    Cho YM; Deerochanawong C; Seekaew S; Suraamornkul S; Benjachareonwong S; Sattanon S; Chamnan P; Sirirak T; Kosachunhanun N; Pratipanawatr T; Suwanwalaikorn S; Lee WJ; Kim S; Choi S; Kang ES; Oh T; Kwon S; Lee MK
    Diabetes Obes Metab; 2020 Jan; 22(1):123-127. PubMed ID: 31478335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative efficacy and safety of gemigliptin versus linagliptin in type 2 diabetes patients with renal impairment: A 40-week extension of the GUARD randomized study.
    Han SY; Yoon SA; Han BG; Kim SG; Jo YI; Jeong KH; Oh KH; Park HC; Park SH; Kang SW; Na KR; Kang SW; Kim NH; Jang Y; Kim B; Shin S; Cha DR
    Diabetes Obes Metab; 2018 Feb; 20(2):292-300. PubMed ID: 28719008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 52-week extension study of switching from gemigliptin vs sitagliptin to gemigliptin only as add-on therapy for patients with type 2 diabetes who are inadequately controlled with metformin alone.
    Jung CH; Rhee EJ; Lee WY; Min KW; Shivane VK; Sosale AR; Jang HC; Chung CH; Nam-Goong IS;
    Diabetes Obes Metab; 2018 Jun; 20(6):1535-1541. PubMed ID: 29436761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multicentre, multinational, randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of gemigliptin (LC15-0444) in patients with type 2 diabetes.
    Yang SJ; Min KW; Gupta SK; Park JY; Shivane VK; Pitale SU; Agarwal PK; Sosale A; Gandhi P; Dharmalingam M; Mohan V; Mahesh U; Kim DM; Kim YS; Kim JA; Kim PK; Baik SH
    Diabetes Obes Metab; 2013 May; 15(5):410-6. PubMed ID: 23170990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor PF-734200 added to metformin in Type 2 diabetes.
    Rosenstock J; Lewin AJ; Norwood P; Somayaji V; Nguyen TT; Teeter JG; Johnson SL; Dai H; Terra SG
    Diabet Med; 2011 Apr; 28(4):464-9. PubMed ID: 21392067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic cytotoxicity of the dipeptidyl peptidase-IV inhibitor gemigliptin with metformin in thyroid carcinoma cells.
    Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
    Endocrine; 2018 Feb; 59(2):383-394. PubMed ID: 29285650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of food on the pharmacokinetics of gemigliptin/metformin sustained-release 50/1,000 mg (25/500 mg x 2 tablets) fixeddose combination tablet in healthy male volunteers.
    Choi HY; Noh YH; Kim YH; Kim MJ; Lee SH; Kim JA; Kim B; Lim HS; Bae KS
    Int J Clin Pharmacol Ther; 2014 May; 52(5):381-91. PubMed ID: 24495314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gemigliptin, a novel dipeptidyl peptidase-4 inhibitor, exhibits potent anti-glycation properties in vitro and in vivo.
    Jung E; Kim J; Kim SH; Kim S; Cho MH
    Eur J Pharmacol; 2014 Dec; 744():98-102. PubMed ID: 25448307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the potential for pharmacokinetic and pharmacodynamic interactions between dutogliptin, a novel DPP4 inhibitor, and metformin, in type 2 diabetic patients.
    Li J; Klemm K; O'Farrell AM; Guler HP; Cherrington JM; Schwartz S; Boyea T
    Curr Med Res Opin; 2010 Aug; 26(8):2003-10. PubMed ID: 20583949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of ketoconazole and rifampicin on the pharmacokinetics of gemigliptin, a dipeptidyl peptidase-IV inhibitor: a crossover drug-drug interaction study in healthy male Korean volunteers.
    Noh YH; Lim HS; Jin SJ; Kim MJ; Kim YH; Sung HR; Choi HY; Bae KS
    Clin Ther; 2012 May; 34(5):1182-94. PubMed ID: 22534255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Absorption, distribution, metabolism and excretion of gemigliptin, a novel dipeptidyl peptidase IV inhibitor, in rats.
    Kim Y; Kim U; Kim IS; Lee SH; Lee J; Kim DH; Yoo HH
    Xenobiotica; 2014 Jul; 44(7):627-34. PubMed ID: 24738939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of renal impairment and haemodialysis on the pharmacokinetics of gemigliptin (LC15-0444).
    Shon JH; Kim N; Park SJ; Oh MK; Kim EY; Lee SH; Kim YH; Shin JG
    Diabetes Obes Metab; 2014 Oct; 16(10):1028-31. PubMed ID: 24641348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in combination with metformin.
    Fass AD; Gershman JA
    Adv Ther; 2013 Apr; 30(4):337-53. PubMed ID: 23605247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.